Reported Earnings • Jul 12
Second quarter 2026 earnings released: kr1.58 loss per share (vs kr9.13 loss in 2Q 2025) Second quarter 2026 results: kr1.58 loss per share (improved from kr9.13 loss in 2Q 2025). Net loss: kr29.9m (loss narrowed 38% from 2Q 2025). Board Change • Jun 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonas Jarvius was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 28
Q-linea AB (publ), Annual General Meeting, May 27, 2026 Q-linea AB (publ), Annual General Meeting, May 27, 2026, at 15:00 W. Europe Standard Time. Location: advokatfirman lindahl premises, at vaksalagatan 10 in uppsala, uppsala Sweden Announcement • Nov 12
Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 312.3852 million. Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 312.3852 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,495,408
Price\Range: SEK 25
Transaction Features: Rights Offering Announcement • Sep 19
Q-linea AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 321.84365 million. Q-linea AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 321.84365 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,873,746
Price\Range: SEK 25
Transaction Features: Rights Offering Announcement • Jun 27
Q-linea AB (publ) Announces Board Appointments, Effective 26 June 2025 Q-linea AB (publ) at its annual general meeting held on 26 June 2025, approved to elect Johan Bygge and Sebastian Backlund, as members of the board of directors for the period until the end of the next annual general meeting. The annual general meeting also resolved to appoint Johan Bygge as chairman of the board. Announcement • May 16
Q-linea AB (publ), Annual General Meeting, Jun 26, 2025 Q-linea AB (publ), Annual General Meeting, Jun 26, 2025. Announcement • Feb 28
Q-linea AB (publ) to Report Q4, 2024 Results on Feb 28, 2025 Q-linea AB (publ) announced that they will report Q4, 2024 results at 7:30 AM, Central European Standard Time on Feb 28, 2025 Announcement • Feb 01
Vikas Gupta Joins Q-Linea AB (publ) as Senior Director of Clinical Affairs, Effective February 1, 2025 Q-linea AB (publ) announced that Dr. Vikas Gupta, PharmD, FIDSA, a Fellow of the Infectious Diseases Society of America, joins the company as Senior Director of Clinical Affairs, effective February 1, 2025. Dr. Gupta brings decades of experience in the industry, including eight years at Becton, Dickinson and Company and dozens of publications. His recent work regarding antimicrobial resistance rates in oncology patients, as well as the impacts of delayed time to antibiotic therapy on mortality and length of stay for bacteremia patients, is especially relevant to Q-linea's mission. Dr. Gupta is a seasoned clinical pharmacist with experience in patient care and developing and implementing clinical programs in academic and non-academic settings. He earned his Doctor of Pharmacy degree from the University of Illinois, College of Pharmacy and completed his residency in Clinical Pharmacy Practice at the Hospital of the University of Pennsylvania. New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr199m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (kr3.5m revenue, or US$322k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr36m net loss in 3 years). Market cap is less than US$100m (€15.1m market cap, or US$16.1m). Reported Earnings • Nov 05
Third quarter 2024 earnings released: kr0.36 loss per share (vs kr0.56 loss in 3Q 2023) Third quarter 2024 results: kr0.36 loss per share (improved from kr0.56 loss in 3Q 2023). Net loss: kr42.4m (loss narrowed 13% from 3Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Announcement • Oct 24
Q-linea AB (publ) Announces the Initiation of a DOOR MAT Study at a Large US Academic Medical Center Q-linea AB (publ) announced the initiation of a DOOR MAT study, a first of its kind using the ASTar®? instrument. A Desirability of Outcome Ranking Approach for the Management of Antimicrobial Therapy (DOOR MAT) analysis balances patient outcomes and antimicrobial stewardship goals. The study will be conducted at a large academic center on the US east coast and will complement existing and ongoing analytical and health economics studies, adding to the growing body of evidence of the impacts of the ASTar system. Study authors anticipate that the use of rapid antibiotic susceptibility test results will lead to a hypothetical reduction in days of broad spectrum and inappropriate antibiotic therapy when retrospective chart analyses are completed. Announcement • Oct 21
Q-Linea AB (Publ) Announces US Reference Laboratory Completes ASTar®? Evaluation Q-linea AB (publ) announced that a US reference laboratory has completed their analytical evaluation of the ASTar instrument and Gram-negative blood culture panel. The company is now in discussions with the reference laboratory leadership regarding next steps for implementation of ASTar for routine clinical use. Additional evaluations are ongoing at several US academic medical centers. Interest in adoption and implementation of the ASTar system continues to grow due to the fully automated nature of the instrument, low hands-on time, high throughput, and ease of use. Announcement • Sep 26
Q-linea AB (publ) Presents Interim Evaluation Data on Webinar Q-linea AB (publ) announced webinar titled Clinical Evaluation of an FDA- Cleared High-Throughput Rapid Antibiotic Susceptibility Testing System hosted 360Dx. Q-linea partnered with 360Dx to host a webinar that is now available for playback on demand. The webinar featured Dr. Elizabeth Garrett of Penn State College of Medicine and Dr. Rebecca Yee of George Washington University discussing interim results from their respective evaluations of the ASTar system. These microbiology labs each receive between 15,000 and 30,000 blood cultures annually. In both laboratories, the ASTar produced minimum inhibitory concentration (MIC) results approximately 36 hours faster than the standard of care instruments, providing opportunities for earlier interventions by clinicians to optimize antibiotic therapy. The presenters also highlighted the ease of use of the system and positive feedback from technicians using the instrument, as well as the value of consumables that can be stored at room temperature. The study design also includes partnering with the hospitals' antimicrobial stewardship teams to conduct retrospective chart reviews to determine what actions clinicians may have taken with access to the rapid antibiotic susceptibility test (AST) results. In an early dataset from George Washington University, chart reviews revealed that 44% of patients would have been exposed to fewer antibiotics had the study results been available clinically. Additionally, the rapid AST results would have enabled antibiotic de-escalation in 33% of patients, antibiotic escalation in 22% of patients, and potential reduction in length of stay in 22% of patients. Next steps for both hospital labs include completing enrollment of patient samples, finalizing retrospective chart reviews, and preparing a manuscript to publish their findings. Reported Earnings • Jul 12
Second quarter 2024 earnings released: kr0.56 loss per share (vs kr2.23 loss in 2Q 2023) Second quarter 2024 results: kr0.56 loss per share. Net loss: kr65.8m (loss widened 1.1% from 2Q 2023). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Announcement • Jun 28
Q-linea AB (publ) Approves the Election of Jonas Jarvius as Members of the Board of Directors Q-linea AB (publ) at its annual general meeting held on 28 June 2024 approved the election of Jonas Jarvius, as members of the board of directors for the period until the end of the next annual general meeting. Reported Earnings • Jun 04
First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023) First quarter 2024 results: kr0.48 loss per share (improved from kr2.10 loss in 1Q 2023). Net loss: kr56.0m (loss narrowed 8.9% from 1Q 2023). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Apr 16
Full year 2023 earnings released: kr3.48 loss per share (vs kr9.20 loss in FY 2022) Full year 2023 results: kr3.48 loss per share (improved from kr9.20 loss in FY 2022). Net loss: kr229.4m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. New Risk • Mar 05
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: kr229m Forecast net loss in 3 years: kr80m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr236m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Revenue is less than US$1m (kr6.6m revenue, or US$639k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr80m net loss in 3 years). Market cap is less than US$100m (€22.3m market cap, or US$24.2m). Breakeven Date Change • Mar 05
No longer forecast to breakeven The 2 analysts covering Q-linea no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr15.0m in 2026. New consensus forecast suggests the company will make a loss of kr43.0m in 2026. Reported Earnings • Feb 28
Full year 2023 earnings released: kr3.48 loss per share (vs kr9.20 loss in FY 2022) Full year 2023 results: kr3.48 loss per share (improved from kr9.20 loss in FY 2022). Net loss: kr229.4m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 01
Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024 Anders Ljunggren takes office as Managing Director of Q-linea AB on 1 March 2024. Anders Ljunggren will support Stuart Gander, who as previously communicated, will take over as Group CEO as of 1 March 2024. Anders Ljunggren will be based in Uppsala and thus work as a strong bridge between Uppsala and the US where Stuart Gander is initially based. Anders Ljunggren has extensive experience from the healthcare industry, with a focus on diagnostics and medical technology. In recent years, he has led the project organization at Q-linea and has previously worked with, among others, Tobii and GE Healthcare. Anders has a deep knowledge of Q-linea's various departments and is a member of the company's management team. Announcement • Jan 23
Q-linea AB (publ) Announces CEO Changes Q-linea AB (publ) announced that Stuart Gander succeeds Jonas Jarvius as CEO. Stuart Gander brings extensive experience from leading positions in the global healthcare industry, with a focus on diagnostics and medical technologies. Through his management consulting background, he has supported companies on a range of operational challenges with a focus on driving sustainable change and growth, based on building strong and motivated teams. Stuart Gander is a Canadian citizen, has previously been working 15 years in Sweden, is currently living in the USA but will relocate to Sweden within the next 18 months. Announcement • Jan 15
Q-linea AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024 Q-linea AB (publ) announced that they will report fiscal year 2023 results at 7:30 AM, Central European Standard Time on Feb 27, 2024 Breakeven Date Change • Dec 31
Forecast to breakeven in 2026 The 2 analysts covering Q-linea expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr43.0m in 2026. Average annual earnings growth of 44% is required to achieve expected profit on schedule. New Risk • Nov 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr267m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr267m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Revenue is less than US$1m (kr6.3m revenue, or US$581k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$34.1m). Reported Earnings • Nov 04
Third quarter 2023 earnings released: kr0.56 loss per share (vs kr2.03 loss in 3Q 2022) Third quarter 2023 results: kr0.56 loss per share (improved from kr2.03 loss in 3Q 2022). Net loss: kr48.6m (loss narrowed 18% from 3Q 2022). Revenue is forecast to grow 80% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Announcement • Jul 26
Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million. Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 87,628,425
Price\Range: SEK 3
Transaction Features: Rights Offering New Risk • Jul 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr269m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Revenue is less than US$1m (kr5.3m revenue, or US$511k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr29m net loss in 3 years). Market cap is less than US$100m (€43.2m market cap, or US$47.8m). Announcement • Jul 18
Q-linea AB (publ) Completes its 510(k) Application for US Market Approval Q-linea AB (publ) announced that the company has completed its 510(k) application for US market approval. At the FDA's recommendation, Q-linea conducted additional analytical and clinical studies to support the company's 510(k) application for U.S. market authorization. Q-linea has had a continuous dialogue with the FDA, something that has likely been facilitated by ASTar's Breakthrough Device designation. As previously communicated, however, it is difficult to assess the timing of market approval in the US. The FDA may have additional questions and the processing time is hard to estimate. The FDA's recommendation to conduct additional testing was prompted by an algorithm update and was primarily aimed at verifying the performance improvements brought about by the algorithm update. The update was made as training data was expanded after the clinical study in the 510(k) application was completed. The training data is the basis for the machine learning algorithms that AStar's software uses to calculate results. Similar performance improvements for ASTar are already implemented for the European market. Reported Earnings • Jul 14
Second quarter 2023 earnings released: kr2.23 loss per share (vs kr2.53 loss in 2Q 2022) Second quarter 2023 results: kr2.23 loss per share (improved from kr2.53 loss in 2Q 2022). Net loss: kr65.0m (loss narrowed 12% from 2Q 2022). Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Announcement • Jun 15
Q-linea AB (publ) Announces First Patient Enrolls in Lifetimes Q-linea AB (publ) announced that the first patient has been enrolled in Lifetimes, a Q-linea sponsored multicentre study investigating the health and economic benefits of using ASTar when treating ICU patients with bloodstream infections. The study will enroll 160 prospective ICU patients, including adults and children, treated for Gram-negative bacteraemia at four major Italian hospitals. The study aims to investigate the impact of using ASTar on time to optimal therapy, ICU and hospital length of stay, duration, and cost of antibiotic therapy. It is expected to last approximately one year. Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Nina Korfu-Pedersen was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 17
Full year 2022 earnings released Full year 2022 results: kr9.20 loss per share. Net loss: kr268.7m (flat on FY 2021). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 17
Full year 2022 earnings released: kr9.20 loss per share (vs kr8.19 loss in FY 2021) Full year 2022 results: kr9.20 loss per share (further deteriorated from kr8.19 loss in FY 2021). Net loss: kr268.7m (loss widened 16% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Announcement • Feb 17
Q-linea AB (publ) Announces CFO Changes, Effective May 1, 2023 Q-linea AB (publ) announced that the company has hired Christer Samuelsson as CFO and IR. Christer Samuelsson takes office on May 1, 2023 when he succeedsAnders Lundin, who has held the position since 2018. Anders Lundin will end his contract in connection with the annual general meeting in May 2023. Christer Samuelsson has solid experience as CFO from several industries, partly in life science, but also from fast-growing listed and unlisted companies in the renewable energy sector. In addition, Christer has many years of experience from the financial sector. Announcement • Feb 15
Q-linea AB (publ) Prepare to Start Additional Testing for US 510(K) Application Q-linea AB (publ) announced that, following feedback from the FDA, the Company will initiate additional testing to verify performance improvements that were implemented after the completion of the clinical validation in the 510(k) application for US market approval. The 510(k) application was originally submitted in June 2022. The FDA's recommendation to conduct additional testing is prompted by an algorithm update and is primarily aimed at verifying the performance improvements brought about by the algorithm update. The update was made after the training data was expanded after the clinical study in the 510(k) application was completed. The training data is the basis for the machine learning algorithms that the ASTar software uses to calculate results. Similar performance improvements are already implemented and approved in the ASTar instruments approved for the European market. The testing will be carried out at two locations in the USA and in the company's own microbiology laboratory in Uppsala and is estimated to include 300-350 samples from positive blood cultures. Announcement • Dec 14
Q-Linea Participates in Comparative Rapid AST Study Q-linea AB (publ) announced that the company will participate in a study comparing the benefits of three different rapid AST devices to current standard of care. A total of 240 patients treated for Gram-negative septicemia will be enrolled in the study at a major European hospital. Septicemia is a bacterial infection that spreads into the bloodstream and sepsis can be the body's response to that infection. Positive blood culture samples will be analyzed using three rapid phenotypic AST systems. Diagnostic performance, workflow adaptability, and reduction in time to optimal antibiotic treatment for the three systems will be compared to the current standard of care method. Reported Earnings • Nov 01
Third quarter 2022 earnings released: kr2.03 loss per share (vs kr1.68 loss in 3Q 2021) Third quarter 2022 results: kr2.03 loss per share (further deteriorated from kr1.68 loss in 3Q 2021). Net loss: kr59.4m (loss widened 21% from 3Q 2021). Revenue is forecast to grow 166% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jul 15
Second quarter 2022 earnings released: kr2.53 loss per share (vs kr2.47 loss in 2Q 2021) Second quarter 2022 results: kr2.53 loss per share (down from kr2.47 loss in 2Q 2021). Net loss: kr74.0m (loss widened 8.9% from 2Q 2021). Over the next year, revenue is forecast to grow 384%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year. Reported Earnings • May 06
First quarter 2022 earnings released: kr2.46 loss per share (vs kr2.34 loss in 1Q 2021) First quarter 2022 results: kr2.46 loss per share (down from kr2.34 loss in 1Q 2021). Net loss: kr71.9m (loss widened 14% from 1Q 2021). Over the next year, revenue is forecast to grow 1,343%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • Apr 26
Q-linea AB (publ) Announces Marcus Storch Not Available for Re-Election as Member of Board of Directors Q-linea AB (publ) at its annual general meeting to be held on May 24, 2022, announced that Marcus Storch has informed the Nomination Committee that he is not available for re-election as member of the board of directors. Reported Earnings • Apr 17
Full year 2021 earnings released: kr8.19 loss per share (vs kr8.64 loss in FY 2020) Full year 2021 results: kr8.19 loss per share. Net loss: kr231.2m (loss widened 5.8% from FY 2020). Over the next year, revenue is forecast to grow 1,629%, compared to a 11% growth forecast for the industry in Germany. Board Change • Mar 04
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Mario Gualano was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Feb 23
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 29%. The fair value is estimated to be kr9.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% per annum over the last 3 years. Earnings per share has been flat over the last 3 years. Breakeven Date Change • Feb 19
Forecast breakeven date pushed back to 2024 The analyst covering Q-linea previously expected the company to break even in 2023. New forecast suggests losses will reduce by 17% per year to 2023. The company is expected to make a profit of kr87.0m in 2024. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr8.19 loss per share (up from kr8.64 loss in FY 2020). Net loss: kr231.2m (loss widened 5.8% from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 3,446%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Breakeven Date Change • Nov 15
Forecast to breakeven in 2023 The analyst covering Q-linea expects the company to break even for the first time. New forecast suggests the company will make a profit of kr52.0m in 2023. Average annual earnings growth of 91% is required to achieve expected profit on schedule. Reported Earnings • Nov 06
Third quarter 2021 earnings released: kr1.68 loss per share (vs kr1.80 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr49.1m (loss widened 1.0% from 3Q 2020). Breakeven Date Change • Sep 15
Forecast to breakeven in 2023 The analyst covering Q-linea expects the company to break even for the first time. New forecast suggests the company will make a profit of kr62.0m in 2023. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 07
Forecast to breakeven in 2023 The analyst covering Q-linea expects the company to break even for the first time. New forecast suggests the company will make a profit of kr62.0m in 2023. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Breakeven Date Change • Jul 20
Forecast to breakeven in 2023 The analyst covering Q-linea expects the company to break even for the first time. New forecast suggests losses will reduce by 47% per year to 2022. The company is expected to make a profit of kr62.0m in 2023. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Reported Earnings • Jul 18
Second quarter 2021 earnings released: kr2.47 loss per share (vs kr2.37 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr67.9m (loss widened 18% from 2Q 2020). Recent Insider Transactions • Jun 13
CEO & President recently sold €1.4m worth of stock On the 10th of June, Jonas Jarvius sold around 95k shares on-market at roughly €14.47 per share. This was the largest sale by an insider in the last 3 months. This was Jonas' only on-market trade for the last 12 months. Announcement • Jun 11
Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million. Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,200,000
Price\Range: SEK 137 Announcement • Jun 08
Q-linea AB (publ) Initiates US 510(k) Clinical Study for ASTar Q-linea AB (publ) announced that the company has started the 510(k) US clinical study for ASTar. The structure of the study will follow the design of the European clinical study starting at Q-linea with analytical and retrospective spike-in samples and then expand to US hospitals for the prospective part of the study. The size of the US study will be slightly larger compared to the European study with an expanded analytical study according to FDA guidelines and is planned to include up to 150 prospective patient samples each from participating hospitals. The focus of the study will be antimicrobial susceptibility results for gram- negative bacteria, including fastidious, directly from positive blood cultures. Reported Earnings • May 07
First quarter 2021 earnings released: kr2.34 loss per share (vs kr2.44 loss in 1Q 2020) First quarter 2021 results: Net loss: kr63.2m (loss widened 13% from 1Q 2020). Reported Earnings • Apr 20
Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019) Full year 2020 results: Net loss: kr218.7m (loss widened 23% from FY 2019). Announcement • Mar 12
Q-linea AB (publ) Receives First Order on ASTar Q-linea AB (publ) announced that the company's global sales partner Thermo Fisher Scientific has placed their first order on ASTar® instruments and consumables. The value of the order exceeds SEK 8 million. ASTar is a fully automatic system for antibiotic susceptibility testing (AST) with little hands-on time, ease-of- use and capabilities to deliver a broad answer within approximately six hours for positive blood cultures. This order aims to enable commercial readiness for the first customer orders after launch. Commercial launch can take place as soon as the clinical study is finalized and ASTar is CE-IVD approved. ASTar´s first application is focused on improving the diagnostics for patients with blood stream infections, where sepsis is the most common condition. The value of the first order from Thermo Fisher Scientific exceeds SEK 8 million. The structure of the order also includes a pre-payment for a binding order for the next six months. Both Thermo Fisher Scientific and Q-linea believe in a strong growth for ASTar and aim for a long term successful and strong ramp-up after the first controlled launch phase. Reported Earnings • Feb 20
Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019) Full year 2020 results: Net loss: kr218.7m (loss widened 23% from FY 2019). Analyst Estimate Surprise Post Earnings • Feb 20
Revenue beats expectations Revenue exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 7,991%, compared to a 15% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Feb 11
New 90-day low: €14.35 The company is down 9.0% from its price of €15.85 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 28
New 90-day high: €17.40 The company is up 30% from its price of €13.35 on 29 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Dec 11
Q-linea AB Initiates Pivotal Clinical Study for ASTar in Europe Q-linea AB (publ) announced that the company has started the pivotal clinical study for ASTar in Europe. The pivotal study for Europe is estimated to include 60-80 prospective patient samples from Hvidovre Hospital in Denmark and Uppsala University Hospital, and approximately 600 samples that are analyzed internally. Most of the internal samples consist of so-called spike-in analysis where bacteria collected from different parts of the world with different resistance patterns are analyzed together with blood from healthy donors. The results of the study will be part of the documentation in the ongoing process for CE-IVD approval prior to the market launch of ASTar. Is New 90 Day High Low • Nov 11
New 90-day high: €15.90 The company is up 36% from its price of €11.70 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Reported Earnings • Nov 07
Third quarter 2020 earnings released: kr1.80 loss per share Third quarter 2020 results: Net loss: kr48.7m (loss widened 39% from 3Q 2019). 
